CM
CMPX icon

CM Management’s Compass Therapeutics CMPX Stock Holding History

CM Management’s Portfolio CMPX Stock Details CMPX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-100,000
Closed -$537K – 73
2025
Q4 		$537K Sell
100,000
-50,000
-33% -$231K 0.45% 52
2025
Q3 		$525K Buy
+150,000
New +$474K 0.44% 57
2025
Q1 		– Sell
-310,000
Closed -$450K – 55
2024
Q4 		$450K Hold
310,000
– – 0.4% 51
2024
Q3 		$570K Hold
310,000
– – 0.46% 54
2024
Q2 		$310K Hold
310,000
– – 0.28% 59
2024
Q1 		$614K Buy
310,000
+185,000
+148% +$320K 0.52% 53
2023
Q4 		$195K Buy
+125,000
New +$216K 0.16% 70
2022
Q3 		– Sell
-30,000
Closed -$80K – 73
2022
Q2 		$80K Sell
30,000
-270,000
-90% -$586K 0.09% 69
2022
Q1 		$411K Buy
+300,000
New +$620K 0.35% 67

Other funds holding CMPX

TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
SCM
Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return
VC
Vivo Capital Palo Alto, California $1.2B AUM 911.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
ES
Enavate Sciences Menlo Park, California $352M AUM 220.14% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

CM Management's CMPX Position: Q1 2026 in Review

CM Management sold out of Compass Therapeutics (CMPX) in Q1 2026, closing a stake of 100,000 shares — an estimated $537K sold.

CM Management first reported a position in CMPX in Q1 2022 and held it in 9 quarters. The position peaked at $614K in Q1 2024. 201 funds tracked by Wall St. Rank hold CMPX as of Q1 2026.

  • CM Management reported no remaining Compass Therapeutics position as of Q1 2026 after selling out during the quarter.
  • CM Management sold 100,000 Compass Therapeutics shares in Q1 2026, an estimated $537K.
  • CM Management first reported a position in Compass Therapeutics in Q1 2022 and held it in 9 quarters.
  • CM Management's Compass Therapeutics position peaked at $614K in Q1 2024.
  • 201 funds tracked by Wall St. Rank held Compass Therapeutics as of Q1 2026.

Based on CM Management's 13F filing for Q1 2026, filed 8 May 2026.